81 related articles for article (PubMed ID: 22529231)
21. Cardiovascular primary prevention: how high should we set the bar?
Prasad V; Vandross A
Arch Intern Med; 2012 Apr; 172(8):656-9; discussion 659. PubMed ID: 22529231
[TBL] [Abstract][Full Text] [Related]
22. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
23. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
Gotto AM; Farmer JA
Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799
[TBL] [Abstract][Full Text] [Related]
24. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
Daskalopoulou SS; Mikhailidis DP
Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
[TBL] [Abstract][Full Text] [Related]
25. Influence and critique of the JUPITER Trial (Statins v no statins for primary prevention of cardiovascular events in patients with normal lipids and elevated C-reactive protein).
Samson RH; Nair DG
Semin Vasc Surg; 2011 Sep; 24(3):172-9. PubMed ID: 22153029
[TBL] [Abstract][Full Text] [Related]
26. Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant.
Ahmed MH; Khalil AA
Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1021-9. PubMed ID: 21060168
[TBL] [Abstract][Full Text] [Related]
27. Statin and ezetimibe combination therapy in cardiovascular disease.
Dembowski E; Davidson MH
Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):183-8. PubMed ID: 19262375
[TBL] [Abstract][Full Text] [Related]
28. The facts behind niacin.
Hochholzer W; Berg DD; Giugliano RP
Ther Adv Cardiovasc Dis; 2011 Oct; 5(5):227-40. PubMed ID: 21893559
[TBL] [Abstract][Full Text] [Related]
29. A clinical focus on statins.
Auer J; Eber B
Curr Opin Investig Drugs; 2001 Mar; 2(3):382-8. PubMed ID: 11575709
[TBL] [Abstract][Full Text] [Related]
30. [Primary and secondary prevention of coronary disease by statins].
Ferrières J
Ann Cardiol Angeiol (Paris); 1999 Feb; 48(2):128-36. PubMed ID: 12555337
[TBL] [Abstract][Full Text] [Related]
31. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
Jacobson TA
Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
[TBL] [Abstract][Full Text] [Related]
32. The ezetimibe controversy: implications for clinical practice.
Khanderia U; Regal RE; Rubenfire M; Boyden T
Ther Adv Cardiovasc Dis; 2011 Aug; 5(4):199-208. PubMed ID: 21636623
[TBL] [Abstract][Full Text] [Related]
33. [Target levels for LDL cholesterol are put out of the running. Cholesterol should be lowered maximally in high cardiovascular risk].
Olsson AG
Lakartidningen; 2011 Jun 1-14; 108(22-23):1240-3. PubMed ID: 21786498
[No Abstract] [Full Text] [Related]
34. Lipid-lowering effects of ezetimibe and simvastatin in combination.
Ijioma N; Robinson JG
Expert Rev Cardiovasc Ther; 2011 Feb; 9(2):131-45. PubMed ID: 21453210
[TBL] [Abstract][Full Text] [Related]
35. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
[TBL] [Abstract][Full Text] [Related]
36. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
[TBL] [Abstract][Full Text] [Related]
37. Clinical use of ezetimibe.
Cheng AY; Leiter LA
Can J Clin Pharmacol; 2003; 10 Suppl A():21A-5A. PubMed ID: 14571302
[TBL] [Abstract][Full Text] [Related]
38. Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.
Robinson JG; Davidson MH
Expert Rev Cardiovasc Ther; 2006 Jul; 4(4):461-76. PubMed ID: 16918265
[TBL] [Abstract][Full Text] [Related]
39. ["The lower LDL cholesterol levels, the better" still valid. Negative/neutral conclusions of three studies on statins do not change the clinical practice].
Olsson AG; Nilsson PM
Lakartidningen; 2009 Mar 18-24; 106(12):854-7. PubMed ID: 19452786
[No Abstract] [Full Text] [Related]
40. [Guideline for management of lipid metabolism].
Ishibashi S
Nihon Rinsho; 2002 Sep; 60 Suppl 9():675-8. PubMed ID: 12387068
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
